ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 986,77
-0,97%
Dow Jones
38 087,06
-0,78%
DAX
17 949,40
-1,01%
Brent Oil
86,29
-1,14%
Bitcoin
60 860,62
-4,66%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Immutep Ltd (IMMP)

  7. Immutep Ltd (IMMP) Actualités

IMMP Immutep Ltd

2,64
-0,03 (-1,12%)
Dernière mise à jour : 17:07:45
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Immutep Ltd IMMP NASDAQ Certificat de dépôt
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,03 -1,12% 2,64 17:07:45
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
2,69 2,62 2,76 2,67
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
29/4/202414:00GLOBEImmutep Quarterly Activities Report Q3 FY24
24/4/202414:00GLOBEImmutep Announces Positive Preliminary Topline Results from..
18/4/202414:00GLOBEImmutep Appoints Leading Research Institute to Conduct..
17/4/202414:00GLOBEImmutep Receives Positive Feedback from the Spanish..
05/3/202414:00GLOBEImmutep Announces First Clinical Data from 90mg Dosing of..
30/1/202422:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/1/202414:00GLOBEImmutep Quarterly Activities Report Q2 FY24
04/1/202414:00GLOBEFirst Patient Dosed in Trial Evaluating Efti and the..
21/12/202314:00GLOBEImmutep Receives Constructive Regulatory Feedback on..
21/12/202312:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/12/202314:00GLOBEImmutep Receives A$2.6 million R&D Tax Incentive from French..
22/11/202314:00GLOBEImmutep Announces Site Expansion for INSIGHT-003 Phase I..
09/11/202314:00GLOBEImmutep Completes Enrollment in TACTI-003 Phase IIb Trial of..
06/11/202314:00GLOBEImmutep Announces Completion of the Safety Lead-In and..
03/11/202317:00GLOBEImmutep Announces New Biomarker Data from TACTI-002 Phase II..
03/11/202311:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/11/202313:00GLOBEImmutep to Participate in November Investor Events
31/10/202313:00GLOBEImmutep Quarterly Activities Report Q1 FY24
25/10/202314:00GLOBEImmutep receives ~A$1.13 million R&D Tax Incentive
25/10/202312:07EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24/10/202314:00GLOBEImmutep Reports Promising Clinical Data from INSIGHT-003..
24/10/202312:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
23/10/202314:00GLOBEImmutep’s Efti in Combination with KEYTRUDA® Generates..
16/10/202314:00GLOBEImmutep Announces Publication of Abstracts at ESMO Congress..
03/10/202314:00GLOBEImmutep Announces Abstract Accepted for Presentation at the..
21/9/202314:00GLOBECommercial Manufacturing of Eftilagimod Alpha at 2000L Scale..
05/9/202315:00GLOBEImmutep to Participate in September Investor Conferences
01/8/202314:00GLOBEImmutep Receives Positive Scientific Advice from European..
31/7/202314:00GLOBEImmutep Quarterly Activities Report Q4 FY23
28/7/202314:00GLOBEFirst Patient Dosed in Chemotherapy-Free Triple Combination..
28/7/202312:31EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/6/202314:00GLOBEImmutep Completes A$80 Million Capital Raise
20/6/202314:00GLOBEImmutep Granted United States Patent for IMP761, a..
07/6/202314:00GLOBEImmutep to Participate at the Jefferies Healthcare..
05/6/202314:00GLOBEImmutep Reports Final Positive Data in 2nd Line Head and..
02/6/202314:00GLOBEImmutep Successfully Completes Institutional Placement and..
29/5/202314:00GLOBEImmutep Selects Charles River Laboratories for IMP761’s GLP..
26/5/202314:00GLOBEImmutep Announces Publication of Abstracts for ASCO 2023..
25/5/202314:00GLOBEImmutep Doses First Patient in AIPAC-003 Phase II/III Trial..
24/5/202314:00GLOBEImmutep Announces Promising New Clinical Data from Triple..
17/5/202314:00GLOBEImmutep’s Efti in Combination with Pembrolizumab Achieves..
16/5/202314:00GLOBEImmutep Receives Positive Feedback from FDA on Late-Stage..
09/5/202314:00GLOBEImmutep to Participate in the JMP Securities Life Sciences..
02/5/202314:00GLOBEImmutep Announces KOL Event Focused on Eftilagimod Alpha in..
01/5/202314:00GLOBEImmutep Receives Approval to Initiate INSIGHT-005 Trial..

Dernières Valeurs Consultées

NASDAQ
IMMP
Immutep
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés